So I think it's exactly similar to what we do in somatic mutations in solid tissue tumors, but having a blood as another tissue, given that it's very easy to have a sample from a patient and run it and have the same detection technique, then circulating free DNA is actually very helpful for precision medicine.

Do you agree with that, John? I agree entirely.

I mean, it's the ease of access that's very attractive.

And this means that patients in the country also can have the test when they need to, rather than have to come into the big cities to have their biopsy done.

And as Merit said, in some cases, it's very hard to biopsy tissues, especially if patients are very, very ill.

The other value of CFDNA type approach is that we can learn a lot more about the tumor and we can also try to detect recurrence much earlier.

Instead of waiting for the chest X-ray to be abnormal or the MRI scan to show a mass has come back, we look for DNA that's tumor specific early on.

And those are the main target that we would hopefully be able to offer liquid biopsy because they are really sick and they might need a test that is having a shorter turnaround time to give the clinician an idea of how to treat urgently those patients rather than to wait for an invasive biopsy.